REPORT - PROJECT 01 - GROUP 5

Carolin Bayan, Savannah Cattarius, Laura Diekmann, Rositsa Todorovska

07/19/2021

INTRODUCTION

Drug repurposing describes the strategy of reusing drugs that have already been approved for other medical applications. These drugs can obtain a new purpose by using them in a different therapeutic indication. This approach offers several advantages compared to the development and research of novel drugs. Drug repurposing allows researchers to use already approved pharmaceuticals, which helps them face less obstacles regarding potential side effects and the general approval of these drugs. This is due to the fact that the safety of the drugs has already been tested and validated in prior research. Therefore, costs and legal requirements can be reduced which results in a quicker development of new treatment options (Pushpakom et al. 2019).

According to the WHO[1] , cancer is the second leading cause of death in the United States and a major global health problem. In addition, the progress of diagnosing and treating this disease was set back due to the coronavirus disease 2019 (COVID-19) pandemic which resulted in reduced health care capacities (Siegel et al. 2021). Hence, finding new treatment options by repurposing drugs in order to save resources and time seems to be essential for our society.

For our project, we used data obtained from a large screening of 1396 oncological and non-oncological drugs that were tested on 481 different cancer cell lines (Corsello et al. 2020). While also working with the whole data consisting of several different cancer cell lines, in our analysis we particularly focused on the included 30 ovarian cancer cell lines. The American Cancer Society states that ovarian cancer causes more deaths than any other form of cancer being related to the female reproductive system.[2]

In our project, we aimed to answer two main questions:

1. How do different drugs influence ovary cancer cell lines and which are particularly noticeable? How do these drugs affect the other cell lines?

2. Is the sensitivity of different drugs on ovary cancer cell lines connected to specific cancer-related genes or gene knock-outs?

We subdivided our project into smaller steps in order to find answers to these questions.

First, we analyzed the drugs and their influence on the proliferation of cancer cell lines. We were able to identify the most promising drugs and categorized them based on their mechanism of action (MOA).
In addition, we analyzed to what extent the used drug dosage had an effect on the proliferation values of the cancer cell lines and found out that in most cases the higher the dosage the greater the effect on proliferation.

We also investigated the drug response of certain ovarian cancer cell line clusters based on certain gene expression patterns and knockdown scores which showed less correlations than we initially anticipated. Finally, we used the data to perform a linear regression model in order to predict drug efficiency from certain gene mutations or expressions.

---

[1]https://www.who.int/health-topics/cancer#tab=tab_1
[2]https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html

# MOST EFFECTIVE DRUGS AMONG OVARIAN CELL LINES

General Overview

Figure 1: **1.a.** Ovarian Cancer Cell Lines Mean Sensitivity towards Drugs **1.b.** Mean Drug Efficiency regarding Proliferation in Ovarian Cell Lines

Using the provided prism data frame, we extracted the ovarian DepMap_IDs with their proliferation values after drug treatment. In order to get a general overview of our data, we computed two histograms showing the distribution of the mean sensitivity across all ovarian cell lines and all drugs (see Fig. 1). Fig. 1.a. shows that all ovarian cancer cell lines had a mean sensitivity towards the drugs of less than or equal to zero, which showed us that in general, the applied drugs seemed to have a promising effect on their cell growth. The right plot (Fig. 1.b.) shows all values for the mean drug efficiency in ovarian cell lines. Values below zero indicate negative proliferation. In total, 8652 drugs lie below zero. This means that these drugs generally - with regard to their mean values - caused a reduction in cell growth when they were administered to the ovarian cell lines.

Setting a Threshold

In our next step, we further analyzed the prism data set. Our aim was to determine the strongest effect each drug had on the ovarian cancer cell lines in terms of proliferation values - independent of the dosage that was used. For each drug we chose its minimum value which reflects the strongest negative effect on proliferation of the ovarian cell lines. In order to be able to work with a manageable amount of drugs, we decided to set a threshold at the 10 % quantile (see Fig. 2.a.). By doing so, we could focus on the 140 most effective drugs which caused the lowest negative proliferation values in the ovarian cancer cell lines.

Mechanism of Action

While further analyzing the drugs that lie below the 10 % quantile, we focused on categorizing them after their mechanism of action which we found in the data set prism.treat. According to the original study, clustering by the MOAs seems to be a good choice in order to determine whether the drugs are normally used for treating cancer or not (Corsello et al. 2020).

Our results are shown in Fig. 2.b. These are the 45 most common MOAs regarding the drugs that had the most promising effects on the ovarian cancer cell lines.

We further investigated these MOAs and came to the following results.

Figure 2: **2.a.** Most Effective Drug-Proliferation Values in Ovarian Cell Lines **2.b.** Most Frequent MOAs among the Most Effective Drugs

10 out of the 140 drugs below our threshold are Histone deacetylase (HDAC) inhibitors. Their targets include among other things HDAC3, HDAC4, HDAC8. These are epigenetic targets for noncancer drug repurposing candidates (Moreira-Silva et al. 2020) and were also found to be potential anti-cancer agents for inhibiting cancer cell migration and invasion in ovarian cancer (Ahn et al. 2012).

With 9 occurrences, the topoisomerase inhibitors are the second most frequent MOAs we found. However, this is not surprising since these drugs are commonly used in cancer therapy, thus they showed strong effects on the cancer cell lines (Parchment and Pessina 1998). Interestingly, one of the drugs, mitoxantrone, is also used in the disease area neurology/psychiatry and multiple sclerosis[3].

In addition, cyclin-dependent kinase (CDK) inhibitors appeared seven times in our findings regarding the most effective and common MOAs for treating ovarian cancer. Especially the targets CDK4 and CDK6 showed promising results in a different study (Iyengar et al. 2018) as a new therpeutic approach to treat ovarian cancer.

We found 6 proteasome inhibitors to be most effective against ovarian cancer cell lines. They are an important class of drugs against multiple myeloma and cell lymphoma. However, they are currently in clinical trials for other types of cancer (Fricker 2020) which is why it makes sense that we also found them to have promising effects in our analysis.

In a different study, researchers found that epidermal growth factor receptor (EGFR) is not a suitable target for ovarian cancer therapy (Mehner et al. 2017) and seems to be more effective for lung cancer and pancreas cancer therapy. However, we found three EGFR inhibitors with effective impacts on ovarian cancer cell lines.

The remaining three MOAs: Phosphoinositide 3-kinase (PI3K)- (Vanhaesebroeck et al. 2021), B-cell lymphoma (BCL)- (Montero and Letai 2018) and ATPase-inhibitors (Mijatovic, Dufrasne, and Kiss 2012), are all cancer related MOAs. Therefore, all of them are commonly used in cancer therapy which is why it is not surprising that they appeared in our findings.

Dimension Reduction

Our next step included performing k-means and finding the optimal number of clusters which we visualized by computing a principal component analysis (PCA).

---

[3]National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 4212, Mitoxantrone. Retrieved July 11, 2021 from https://pubchem.ncbi.nlm.nih.gov/compound/Mitoxantrone.

Figure 3: **3.a.** Variance Explained by Mechanism of Action PCs **3.b.** Elbow Method for Finding Optimal Number of Clusters

Fig. 3.a. shows that the majority of the variance is explained by using the first two principal components. In order to find the most optimal number of clusters for our PCA of PC1 and PC2, we used the elbow method. As a result, the optimal number of clusters seems to be 4 (see Fig. 3.b.).


Figure 4: **4.a.** PC1 vs. PC2 for Ovary Cell Line Clusters **4.b.** PC1 vs. PC2 for CN Values in Ovary Cell Lines

Outlier

Fig. 4.a. shows the clustering for the ovarian cell lines according to their reactions towards the 45 selected drugs (see Fig. 2.b.). They do not cluster in completely distinct clusters but one cell line (ACH-000524) forms its own cluster. We found that interesting, which is why we looked further into that one. According to the data set prism.cl, the outlier cell line belongs to the most prominent lineage subtype: ovary adenocarcinoma. This subtype makes up 28 of the 30 lineage subtypes in our data with the remaining two being brenner tumor

4

and ovary carcinoma. This is why we figured that the lineage subtype could not have been the reason for the cell line forming its own cluster.

We performed several PCAs with the other provided data sets (prism.achilles, prism.exp and prism.cnv) and inspected the behavior of the outlier cell line. When we analyzed the gene transcripts per million (TPM) values and the gene knockdown scores, the cell line ACH-000524 clustered in the biggest clusters together with the other cell lines (not shown). However, the cell line did show a different behavior and clustered separately from the majority according to its gene copy number (CN) values (see Fig. 4.b.). This led us to the hypothesis that its differing behavior (see Fig. 4.a.) could be a result of distinct CN values.

Generally Effective Drugs

Figure 5: Contribution to PC1

In Fig. 5, the contribution of specific drug responses to PC1 for ovary cell line clusters (see Fig. 4.a.) is shown. Drugs with values close to zero show a similar effect on the proliferation among all cell lines - thus, these are generally effective when administered to ovary cancer cell lines. This is the case for the following drugs (see highlighted red in Fig. 5).

The ATPase inhibitor ouabain is normally used to treat hypertension and cardiac arrhythmia - however, a study found that it can have promising effects as a cancer treatment for ER+ breast cancer (Chen et al. 2006). In another study, researchers found that one in three ovarian cancers is ER+ (Harding et al. 1990), which leads to the conclusion that this is why we found that ouabain generally showed positive effects among the ovarian cancer cell lines. The drugs JNJ-26481585 (Arts et al. 2009) and romidepsin (Bertino and Otterson 2011) are HDAC inhibitors that, as mentioned before, in general show promising effects on ovarian cancer cell lines. Therefore, it makes sense that we found them among the five generally most effective drugs. BGT226 is a PI3K inhibitor that is actually being considered as a potential therapeutic treatment option in different solid tumors, including ovarian cancer (Simioni et al. 2015). Amsacrine, a topoisomerase inhibitor, is a chemotherapy drug that is commonly used for acute leukemia as well as Hodgkin's and non-Hodgkin's lymphomas (Ketron et al. 2012). Hence, a general effect on the proliferation of other cancer cell lines such as ovarian cancer seems to be logical.

DRUG EFFECT ON THE CELL LINE TYPES

Mechanism of Action

After finding the drugs with the most effective response in regards to the ovarian cancer cell lines, we now continued our analysis by testing if the efficiency of these drugs is dependent on the cancer cell line type or not. In order to test this we repeated many of the same steps we completed for the ovarian cell lines but on

Figure 6: Most frequent MOAs amongst the most effective drugs

the non-ovary cell lines. We extracted the most negative proliferation value for each drug in each non-ovary cell line, set the threshold to the 10% quantile, and then extracted the most common MOAs.

As can be seen in Fig. 6, all but one of the most frequently occurring MOAs are the same as the most frequently occurring MOAs in ovarian cancer cell lines (see Fig. 2.b.); however, the frequency with which they occur in the other cell lines differs slightly from the frequency with which they occur in the ovarian cell lines. The NFkB pathway inhibitor is the one MOA that appears among the 45 most frequent MOAs in the non-ovarian cell lines three times but not at all in the 45 most frequent MOAs in the ovarian cell lines. Although NFkB pathway inhibitors do occur in the ovary cell lines twice, this is not often enough to have made the top 45 which explains why they are not shown in Fig 2.b. NFkB transcription factors are often used to regulate inflammation and immune responses, cell growth, apoptosis, and the expression of certain viral genes (Gilmore and Herscovitch 2006). Due to the importance of the NFkB transcription factors in regulating these processes, NFkB pathway inhibitors are often used in treating chronic inflammation and cancer (Gilmore and Herscovitch 2006).

Fisher's Exact Tests

After finding the most common MOAs among the ovary and all other cell lines, respectively, the next step in our analysis was to find out if any of these MOAs showed a statistically significant occurrence in ovarian cancer specifically. In order to test this, we decided to perform a Fisher's exact test on all of our selected most common MOAs for ovarian cancer and all other cell lines.

In order for the null hypothesis - that there is no association between the occurrence of specific MOAs and the cell line type (either ovarian or non-ovarian) - to be rejected, the p-value must be smaller than the confidence level of 0.05 (Biau, Jolles, and Porcher 2010). This was not the case with any of the Fisher's tests that we conducted. For the Fisher's tests conducted on the topoisomerase inhibitor, the PI3K inhibitor, the NFkB pathway inhibitor, the HDAC inhibitor, the EGFR inhibitor, the BCL inhibitor, and the ATPase inhibitor, the p-values were equal to one, as were the odds-ratios. This shows without a doubt that the H0-hypothesis cannot be rejected and that there therefore is no association between the occurrence of specific MOAs and the cell line type (either ovarian or the others) for these MOAs. The Fisher's tests conducted on the remaining MOAs all calculate a p-value that is lower than 1, none of which are lower than 0.7, however. The odds ratios for these remaining MOAs are all either larger than one or lower than one, which would suggest a positive/negative association, respectively. Since the corresponding p-values are much larger than the confidence level of 0.05 however, these associations are most likely due to chance and are not true associations. Conclusively, these Fisher's tests have shown that not a single one of the most common MOAs among our cell lines occur so commonly due to an association to a specific cell line (either ovarian or the others).

6

Dimension Reduction

Figure 7: PC1 vs. PC2 for All Cell Line Clusters

As a next step we decided to perform a PCA on all cell lines. We clustered by cell lines in order to test if the ovary cell lines would form their own distinctive cluster regarding the drug response. As can be seen in Fig. 7, this was not the case. The red dots representing the ovary cancer cell lines are distributed across the entire plot, rather than concentrated into one distinctive cluster. The fact that the ovary cell lines did not form their own cluster shows that there seems to be no combining trait among them that would trigger a similar drug response.

Welch's T-Test

Additionally to the PCA clustering in Fig. 4.a. and the PCA clustering above, we also conducted a PCA using only non-ovarian cell lines (not shown). As a final step to find out if the drug response is related to the cell line type, we decided to perform a Welch's unpaired two sided t-test, which was subjected a Bonferroni correction. In order to do this we reduced the prism.treat data frame further. It now included only those cell lines located in clusters two and four from the PCA clusterings for non-ovarian and ovarian cell lines, respectively. We used this data and the above mentioned PCA clustering for the t-test. The resulting p-value was higher than the confidence level of 0.05 which means that the null hypothesis - that there is no association between the mean value of the drug response in ovarian and non-ovarian cell lines - could not be rejected. This shows once again that the drug response seems to be independent of the cell line type in regards to the ovarian or non-ovarian cell lines.

DRUG DOSAGE DEPENDENCY

Boxplot of Proliferation Values

We created a boxplot visualizing the distribution of only the ovary cell proliferation rates in regards to the drug dose (see Fig. 8). We decided to divide the boxplot into 3 stages: low, medium, and high dose. The boxplot shows an inverse correlation between the drug dose and cell proliferation. Consequently, an increased drug dose leads to reduced proliferation rates.

Figure 8: Drug Dosage Dependency of Ovary Cell Line Proliferation

Pearson Correlation

Furthermore, we created a correlation matrix with the dosages of the different drugs per ovary cell line and displayed the Pearson correlation in a heatmap. The blue and the purple squares indicate a high and negative correlation, showing that the higher the drug dosage the smaller the cell proliferation rates become (see Fig. 9). Almost all computed Pearson correlation coefficients are negative, except for the one between 'ACH-000713' and 'exatecan-mesylate.' This particular correlation is positive and thus is an outlier. This visualization of the Pearson correlation values shows that there seems to be a strong correlation between increasing dosages and decreasing proliferation values.

Figure 9: Visualization of the Pearson Correlation Values

COMPARISON OF GENE EXPRESSION PATTERNS

In order to show that the different drug response could not be explained by significant differences in specific gene expression rates, gene knockdowns or copy number variations, we used an unpaired two-sided Welch's t-test that was subjected to a Bonferroni correction. We extracted the ovarian cell lines of the clusters 1 and 3, 1 and 2, as well as 2 and 3 (see Fig. 4.a.) in order to perform multiple t-tests. We did not include cluster 4

since it consisted of only one cell line which would have provided an unrepresentative result. We performed t-tests on these pairs of clusters with the corresponding data extracted from prism.treat, prism.exp, prism.cnv and prism.achilles. We found that there are significant differences regarding the drug response between the clusters 1-3 and 2-3, respectively. However, we did not find any major differences concerning the knockdown scores and gene expression rates. Thus, these values do not seem to be the reason for the differing drug responses. Table 1 shows a selection of the drugs that we found to cause significantly different responses between the clusters. We found semaxanib (Kaur, Kaur, and Singh 2018), alvocidib (Morales and Giordano 2016), and tricholstatin-a (Cui et al. 2019) all to be used in oncology.

Table 1: Selection of Significant Drugs for Clusters 1 and 3

	p_value	Bonferroni	target	disease_area
trichostatin-a	1.27e-05	0.0176843	HDAC inhibitor	Oncology
semaxanib	1.43e-05	0.0198872	VEGFR inhibitor	Oncology
alvocidib	2.45e-05	0.0342022	CDK inhibitor	Oncology

MULTIPLE REGRESSION MODEL

In order to predict drug efficiency from unrelated variables in ovarian cancer cell lines, we built a regression model using the drug disulfiram as the dependent variable. As unrelated variables we chose PCs of the data frames prism.achilles, prism.exp and prism.cnv with regard to the ovarian cell lines. We tested disulfiram since it is currently used to treat alcohol dependency and belongs to the disease area neurology/psychiatry. However, it was found to be effective against arm-level 16q loss which occurs in several tumor types but primarily in breast and ovarian cancer (Corsello et al. 2020). This is why we found that drug interesting with regard to drug repurposing for the treatment of ovarian cancer. We used PC1 to PC3 of prism.achilles and PC1 and PC2 of prism.exp and prism.cnv, respectively.


Figure 10: Pairwise Plots of Chosen Variables

Fig. 10 shows the scatter plots of the explanatory variables. Highly correlated variables should be avoided in a regression model. By choosing PCs to build our regression model, it makes sense that they do not correlate. This is important for successfully computing a linear regression.

Next, we split the cell lines into two groups. We used one group for regression-learning (13 out of 25 cell lines) and the remaining cell lines to check our model. In order to obtain the most reliable results, we split

the cell lines in a random manner. After performing the linear regression, we analyzed the results in order to investigate its accuracy. The first value we looked at to do this was the R-squared value, which describes the percentage of the variance of the dependent variable described by the model (Schneider, Hommel, and Blettner 2010). This means that the higher the R-squared value, the more accurate the model. Our linear regression model, with an R-squared value of 0.5203544 therefore seems to be quite unsatisfactory. Additionally, the adjusted R-squared value is negative which shows that the model is unrepresentative. We also looked at the p-value of the F-statistic, which should be under 0.05 in order for the regression model to be useful (Kronthaler and Zöllner 2020). In our model, the p-value fluctuates around 0.05 with every execution of the code, sometimes being a little higher or a little lower. This also points towards the inaccuracy and instability of our model, since the p-value would stay consistently under the 0.05 significance level if the model were accurate.


Figure 11: **11.a.** Correlation between Residuals and Control **11.b.** Predicted Values vs. Real Values

In order to make the linearity assumption, the residuals should be normally distributed (Kronthaler and Zöllner 2020). We checked this with the help of a q-q plot and saw that this was not fully the case as several values lay outside the qq-line. In addition to that, the residuals show a correlation with our explanatory variables (0.6925645) which again revokes the linearity assumption (see. Fig. 11.a.). However, the residuals do have a mean value close to zero ($3.1900564 \times 10^{-18}$). Finally, we tried to predict the drug efficiency of disulfiram on our remaining group of ovarian cell lines. As you can see in Fig. 11.b., this worked semi-good. Nonetheless, this does correlate with our results of the previous analyses which showed that there is hardly a correlation between the proliferation values of most ovarian cell lines and the other data sets containing gene expression patterns and knockdown scores. Therefore, trying to predict a drug response based on PCs of these data sets is not a sufficient model in this case. We computed the linear regression model prior to the previous analysis steps, which is why we did not know that it might turn out insufficiently.

CONCLUSION

To come back to our two main questions, we found that HDAC-, topoisomerase- and CDK-inhibitors showed promising effects on the proliferation of ovarian cell lines. These were also the most prominent MOAs regarding all the other cell lines which was also proved by several Fisher's tests. They showed that there is no significant difference regarding the effect of these MOAs - whether they were applied on ovarian or non ovarian cell lines. In addition, by performing an unpaired two-sided Welch's t-test, we found that while certain drugs do have differing effects on different cell lines, we could not find a connection that these differences were a result of specific cancer-related genes or gene knock-outs - at least within the clusters we focused on. Therefore, our regression model did not work properly.

REFERENCES

Ahn, Mee Young, Dong O. Kang, Yong Jin Na, Sungpil Yoon, Whan Soo Choi, Keun Wook Kang, Hae Young Chung, Jee H. Jung, Do Sik Min, and Hyung Sik Kim. 2012. "Histone Deacetylase Inhibitor, Apicidin, Inhibits Human Ovarian Cancer Cell Migration via Class II Histone Deacetylase 4 Silencing." *Cancer Letters* 325 (2): 189–99. https://doi.org/https://doi.org/10.1016/j.canlet.2012.06.017.

Arts, Janine, Peter King, Ann Mariën, Wim Floren, Ann Beliën, Lut Janssen, Isabelle Pilatte, et al. 2009. "JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity." *Clinical Cancer Research* 15 (22): 6841–51. https://doi.org/10.1158/10 78-0432.CCR-09-0547.

Bertino, Erin M, and Gregory A Otterson. 2011. "Romidepsin: A Novel Histone Deacetylase Inhibitor for Cancer." *Expert Opinion on Investigational Drugs* 20 (8): 1151–58. https://doi.org/10.1517/13543784.201 1.594437.

Biau, David Jean, Brigitte M. Jolles, and Raphaël Porcher. 2010. "P Value and the Theory of Hypothesis Testing: An Explanation for New Researchers." *Clinical Orthopaedics and Related Research* 468 (3): 885–92. https://doi.org/10.1007/s11999-009-1164-4.

Chen, Jin-Qiang, Ruben G. Contreras, Richard Wang, Sandra V. Fernandez, Liora Shoshani, Irma H. Russo, Marcelino Cereijido, and Jose Russo. 2006. "Sodium/Potasium ATPase (Na+, k+-ATPase) and Ouabain/Related Cardiacglycosides: A New Paradigm for Development of Anti- Breast Cancer Drugs?" *Breast Cancer Research and Treatment* 96 (1): 1–15. https://doi.org/10.1007/s10549-005-9053-3.

Corsello, Steven M., Rohith T. Nagari, Ryan D. Spangler, Jordan Rossen, Mustafa Kocak, Jordan G. Bryan, Ranad Humeidi, et al. 2020. "Discovering the Anticancer Potential of Non-Oncology Drugs by Systematic Viability Profiling." *Nature Cancer* 1 (2): 235–48. https://doi.org/10.1038/s43018-019-0018-6.

Cui, Shu-Nan, Zhao-Yuan Chen, Xiao-Bo Yang, Lin Chen, Yi-Yi Yang, Shang-Wen Pan, Ya-Xin Wang, et al. 2019. "Trichostatin a Modulates the Macrophage Phenotype by Enhancing Autophagy to Reduce Inflammation During Polymicrobial Sepsis." *International Immunopharmacology* 77: 105973. https://doi.org/https://doi.org/10.1016/j.intimp.2019.105973.

Fricker, Lloyd D. 2020. "Proteasome Inhibitor Drugs." *Annual Review of Pharmacology and Toxicology* 60 (1): 457–76. https://doi.org/10.1146/annurev-pharmtox-010919-023603.

Gilmore, T. D., and M. Herscovitch. 2006. "Inhibitors of NF-κb Signaling: 785 and Counting." *Oncogene* 25 (51): 6887–99. https://doi.org/10.1038/sj.onc.1209982.

Harding, M., S. Cowan, D. Hole, L. Cassidy, H. Kitchener, J. Davis, and R. Leake. 1990. "Estrogen and Progesterone Receptors in Ovarian Cancer." *Cancer* 65 (3): 486–91. https://doi.org/10.1002/1097-0142(19900201)65:3%3C486::AID-CNCR2820650319%3E3.0.CO;2-C.

Iyengar, Mangala, Patrick O'Hayer, Alex Cole, Tara Sebastian, Kun Yang, Lan Coffman, and Ronald J. Buckanovich. 2018. "Cdk4/6 Inhibition as Maintenance and Combination Therapy for High Grade Serous Ovarian Cancer." *Oncotarget* 9 (21): 15658–72. https://pubmed.ncbi.nlm.nih.gov/29644000.

Kaur, Jagroop, Baljit Kaur, and Palwinder Singh. 2018. "Rational Modification of Semaxanib and Sunitinib for Developing a Tumor Growth Inhibitor Targeting ATP Binding Site of Tyrosine Kinase." *Bioorganic & Medicinal Chemistry Letters* 28 (2): 129–33. https://doi.org/https://doi.org/10.1016/j.bmcl.2017.11.049.

Ketron, Adam C., William A. Denny, David E. Graves, and Neil Osheroff. 2012. "Amsacrine as a Topoisomerase II Poison: Importance of Drug-DNA Interactions." *Biochemistry* 51 (8): 1730–39. https://doi.org/10.1021/bi201159b.

Kronthaler, F., and S. Zöllner. 2020. *Data Analysis with RStudio: An Easygoing Introduction*. Springer Berlin Heidelberg. https://books.google.de/books?id=bGYQEAAAQBAJ.

Mehner, Christine, Ann L. Oberg, Krista M. Goergen, Kimberly R. Kalli, Matthew J. Maurer, Aziza Nassar, Ellen L. Goode, et al. 2017. "EGFR as a Prognostic Biomarker and Therapeutic Target in

Ovarian Cancer: Evaluation of Patient Cohort and Literature Review." *Genes & Cancer* 8 (5-6): 589–99. https://pubmed.ncbi.nlm.nih.gov/28740577.

Mijatovic, Tatjana, François Dufrasne, and Robert Kiss. 2012. "Na+/k+-ATPase and Cancer." *Pharmaceutical Patent Analyst* 1 (1): 91–106. https://doi.org/10.4155/ppa.12.3.

Montero, Joan, and Antony Letai. 2018. "Why Do BCL-2 Inhibitors Work and Where Should We Use Them in the Clinic?" *Cell Death and Differentiation* 25 (1): 56–64. https://doi.org/10.1038/cdd.2017.183.

Morales, Fatima, and Antonio Giordano. 2016. "Overview of Cdk9 as a Target in Cancer Research." *Cell Cycle* 15 (4): 519–27. https://doi.org/10.1080/15384101.2016.1138186.

Moreira-Silva, Filipa, Vânia Camilo, Vítor Gaspar, João F. Mano, Rui Henrique, and Carmen Jerónimo. 2020. "Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment?" *Pharmaceutics* 12 (5): 410. https://doi.org/10.3390/pharmaceutics12050410.

Parchment, R. E., and A. Pessina. 1998. "Topoisomerase i Inhibitors and Drug Resistance." *Cytotechnology* 27 (1-3): 149–64. https://doi.org/10.1023/A:1008008719699.

Pushpakom, Sudeep, Francesco Iorio, Patrick A. Eyers, K. Jane Escott, Shirley Hopper, Andrew Wells, Andrew Doig, et al. 2019. "Drug Repurposing: Progress, Challenges and Recommendations." *Nature Reviews Drug Discovery* 18 (1): 41–58. https://doi.org/10.1038/nrd.2018.168.

Schneider, Astrid, Gerhard Hommel, and Maria Blettner. 2010. "Linear Regression Analysis: Part 14 of a Series on Evaluation of Scientific Publications." *Deutsches Arzteblatt International* 107 (44): 776–82. https://doi.org/10.3238/arztebl.2010.0776.

Siegel, Rebecca L., Kimberly D. Miller, Hannah E. Fuchs, and Ahmedin Jemal. 2021. "Cancer Statistics, 2021." *CA: A Cancer Journal for Clinicians* 71 (1): 7–33. https://doi.org/https://doi.org/10.3322/caac.21654.

Simioni, Carolina, Alice Cani, Alberto M. Martelli, Giorgio Zauli, Ayman A. M. Alameen, Simona Ultimo, Giovanna Tabellini, James A. McCubrey, Silvano Capitani, and Luca M. Neri. 2015. "The Novel Dual Pi3k/mTOR Inhibitor NVP-Bgt226 Displays Cytotoxic Activity in Both Normoxic and Hypoxic Hepatocarcinoma Cells." *Oncotarget* 6 (19): 17147–60. https://pubmed.ncbi.nlm.nih.gov/26003166.

Vanhaesebroeck, Bart, Matthew W. D. Perry, Jennifer R. Brown, Fabrice André, and Klaus Okkenhaug. 2021. "Pi3k Inhibitors Are Finally Coming of Age." *Nature Reviews Drug Discovery*, June. https://doi.org/10.1038/s41573-021-00209-1.